Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancer
Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
The AMALTHEA (Aflibercept MAintenance after first-Line THErapy with FOLFIRI+Aflibercept in metastatic colorectal cancer patients) trial is an investigator-initiated, single arm, open-label, phase II study.
- Trial name
- AMALTHEA (NCT02129257)
- Testing
- AFLIBERCEPT, Irinotecan, 5-Fluorouracil
- Where
- 18 sites in Greece
- Volunteers
- 73 people
- Sponsor
- Hellenic Cooperative Oncology Group
Metastatic Colorectal Cancer
Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses.
- Trial name
- Epitopes-CRC02 (NCT02817178)
- Testing
- Additional biological samples
- Where
- 9 sites in France
- Volunteers
- 258 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Metastatic Colorectal Cancers, Metastatic Gastric Cancers
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable…
- Conditions
- Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers
- Trial name
- MOMENTUM1 (NCT01843725)
- Testing
- capecitabine, aflibercept
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Metastatic Breast Cancer, Colon Cancer
Safety of Xeloda in Solid Tumours
The primary objective of this study is to observe safety and tolerability of Xeloda as used in medical practice, alone and in combination with docetaxel.
- Trial name
- NCT02479217
- Testing
- Docetaxel, Xeloda
- Where
- Serbia
- Volunteers
- 1,268 people
- Sponsor
- Hoffmann-La Roche
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin.
- Trial name
- NCT01931150
- Testing
- Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
RATIONALE: The use of endoscopy to place metal stents in the duodenum is less invasive than surgery for treating cancer-related duodenal obstruction and may have fewer side effects and improve recovery.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer
- Trial name
- NCT00004910
- Testing
- bowel obstruction management, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Colorectal Cancer
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.
- Trial name
- NCT00203411
- Testing
- Capecitabine (Xeloda), Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Translational Oncology Research International
Metastatic Colorectal Cancer
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
- Trial name
- NCT00252564
- Testing
- Bevacizumab, Oxaliplatin, Leucovorin
- Where
- 82 sites in United States
- Volunteers
- 247 people
- Sponsor
- US Oncology Research
Colorectal Neoplasms
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.
- Trial name
- NCT00077987
- Testing
- SU011248
- Volunteers
- 84 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
This study will evaluate the efficacy and safety of a first-line regimen of Avastin and Xelox (Xeloda + Eloxatin) followed by Avastin and Tarceva, in patients with metastatic colorectal cancer.
- Trial name
- NCT01135498
- Testing
- bevacizumab [Avastin], eloxatin, capecitabine [Xeloda]
- Where
- 12 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Recurrent Colon Cancer, Recurrent Rectal Cancer
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01294826
- Testing
- AUY922, Cetuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Colon Cancer, Immunotherapy
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Trial name
- NCT06573424
- Testing
- Tislelizumab+anlotinib, anlotinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- fan li
Colorectal Neoplasms
Stivarga Real Life Evidence in Hungary
The study aims to evaluate use of regorafenib in clinical practice in Hungary. The study should provide information about clinical characteristics of Hungarian regorafenib patients as well as information about safety and efficacy…
- Trial name
- NCT02656524
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Hungary
- Volunteers
- 400 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.
Iron deficiency has a high prevalence in colorectal cancer patients ranging at ca. 60%. About 70% of these patients suffer from iron deficiency anemia (IDA) which adds both physical and cognitive impediments to an already…
- Trial name
- NCT02469480
- Testing
- FerInject, Ferro sanol
- Where
- 18 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Colorectal Cancer
A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, OMP-21M18, when given in combination with FOLFIRI, a standard drug treatment for advanced colorectal cancer.
- Trial name
- NCT01189942
- Testing
- OMP-21M18
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases
PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with colorectal cancer and resectable metastases.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Chemotherapy
- Trial name
- MIROX (NCT00268398)
- Testing
- oxaliplatin, folinic acid, fluorouracil, oxaliplatin, irinotecan, folinic acid, fluorouracil
- Where
- 32 sites in France
- Volunteers
- 284 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
This is a clinical research study of an investigational (FDA BB-IND 10091) treatment for patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer responds to standard therapies.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- Macrobead (NCT01053013)
- Testing
- RENCA macrobeads
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- The Rogosin Institute
Colon Cancer
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer.
- Trial name
- NCT03442569
- Testing
- Panitumumab, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.